PTC Therapeutics Inc. (NASDAQ:PTCT) shares fell 0.8% on Friday . The company traded as low as $7.22 and last traded at $7.45, with a volume of 432,136 shares traded. The stock had previously closed at $7.51.

A number of brokerages have weighed in on PTCT. Oppenheimer Holdings Inc. reiterated a “buy” rating and issued a $39.00 price objective on shares of PTC Therapeutics in a research report on Sunday, April 17th. Zacks Investment Research downgraded shares of PTC Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday. Wedbush restated a “neutral” rating and set a $11.00 price target on shares of PTC Therapeutics in a research report on Wednesday, March 23rd. Jefferies Group restated a “hold” rating and set a $8.00 price target on shares of PTC Therapeutics in a research report on Friday, May 6th. Finally, Royal Bank Of Canada restated a “sector perform” rating and set a $9.00 price target on shares of PTC Therapeutics in a research report on Monday, April 18th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $36.05.

The stock’s market capitalization is $255.41 million. The firm’s 50 day moving average is $7.40 and its 200-day moving average is $13.09.

PTC Therapeutics (NASDAQ:PTCT) last issued its earnings results on Thursday, May 5th. The biopharmaceutical company reported ($1.22) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.26) by $0.04. During the same period in the previous year, the firm earned ($1.15) EPS. The firm earned $18.90 million during the quarter, compared to analysts’ expectations of $13.74 million. The firm’s revenue was up 152.0% on a year-over-year basis. Equities analysts forecast that PTC Therapeutics Inc. will post ($4.93) earnings per share for the current year.

Several hedge funds have recently modified their holdings of the stock. California State Teachers Retirement System increased its stake in shares of PTC Therapeutics by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 62,719 shares of the biopharmaceutical company’s stock valued at $2,032,000 after buying an additional 1,100 shares during the last quarter. Rhumbline Advisers increased its stake in PTC Therapeutics by 8.1% in the fourth quarter. Rhumbline Advisers now owns 33,247 shares of the biopharmaceutical company’s stock worth $1,077,000 after buying an additional 2,485 shares in the last quarter. ProShare Advisors LLC increased its stake in PTC Therapeutics by 10.6% in the fourth quarter. ProShare Advisors LLC now owns 32,490 shares of the biopharmaceutical company’s stock worth $1,053,000 after buying an additional 3,122 shares in the last quarter. Gratus Capital LLC increased its stake in PTC Therapeutics by 9.7% in the fourth quarter. Gratus Capital LLC now owns 53,350 shares of the biopharmaceutical company’s stock worth $1,729,000 after buying an additional 4,700 shares in the last quarter. Finally, Marshall Wace LLP increased its stake in PTC Therapeutics by 50.6% in the fourth quarter. Marshall Wace LLP now owns 44,410 shares of the biopharmaceutical company’s stock worth $1,439,000 after buying an additional 14,926 shares in the last quarter.

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule therapeutics that focus on post-transcriptional control processes. The Company’s lead product, Translarna (ataluren), is used for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients with age of over five years and older.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.